Axsome Therapeutics (AXSM) 10-K 2023 FY Annual report

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements on:

•

Form S-8 (No. 333-217002);

•

Form S-8 (No. 333-208579);

•

Form S-8 (No. 333-230296);

•

Form S-8 (No. 333-226824);

•

Form S-8 (No. 333-238174);

•

Form S-8 (No. 333-256019);

•

Form S-8 (No. 333-264621);

•

Form S-8 (No. 333-271741);

•

Form S-8 (No. 333-272891); and

•

Form S-3 (No. 333-268664).

of our reports dated February 27, 2023, with respect to the consolidated financial statements of Axsome Therapeutics, Inc., included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2023.

/s/ Ernst & Young LLP

New York, New York

February 23, 2024